Condition: Non Small Cell Lung Cancer · Sponsor: Hanmi Pharmaceutical Company Limited
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Research Site | Beverly Hills, California, United States | — |
| Research Site | Burbank, California, United States | — |
| Research Site 2 | Los Angeles, California, United States | — |
| Research Site | Los Angeles, California, United States | — |
| Research Site | Montebello, California, United States | — |
| Research Site | Orange, California, United States | — |
| Research Site | San Diego, California, United States | — |
| Research Site | Boca Raton, Florida, United States | — |
| Research Site | Honolulu, Hawaii, United States | — |
| Research Site | Evanston, Illinois, United States | — |
| Research Site | Bethesda, Maryland, United States | — |
| Research Site | Boston, Massachusetts, United States | — |
+ 60 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02485652